Milestone Pharmaceuticals has raised $13 million in a round of equity financing. The new funding was led by Pappas Ventures, the Business Development Bank of Canada (BDC) and GO Capital.

Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation also participated in the fundraising. Milestone, which is a cardiovascular drug development company, seeks to use the proceeds for development of its drug MSP-2017 and related products.

Click here for the release from PR Newswire.